The eCoin® device, a fully implanted neuromodulation therapy for overactive bladder (OAB) with refractory urgency urinary incontinence (UUI), was evaluated in a follow-on study to assess its safety, efficacy, and feasibility for reimplantation. Participants, who had previously been part of the eCoin feasibility study, were reimplanted with the new eCoin OAB-02A, which featured a larger battery for improved longevity. The study showed significant improvements in UUI symptoms, with 74% of participants responding positively at 12 weeks and 82% at 24 weeks. A high percentage of participants also reported complete continence, with 36% achieving dryness at the 24-week mark.

The reimplantation procedure, performed in an office setting, was quick and complication-free, with no serious adverse events. Patient-reported outcomes, including quality of life assessments, showed substantial improvement in participants’ symptoms, with 78% of participants feeling “better” or “much better” at both the 12- and 24-week follow-up visits. The results suggest that eCoin offers a sustainable, long-term solution for OAB management. Researchers highlight that its ability to be easily reimplanted as needed may provide a more convenient alternative to traditional third-line therapies such as sacral neuromodulation.

Reference: Kaaki B, English S, Gilling P, et al. Six-Month Outcomes of Reimplantation of a Coin-Sized Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome With Urgency Urinary Incontinence. Female Pelvic Med Reconstr Surg. 2022;28(5):287-292. doi: 10.1097/SPV.0000000000001105.